STA
XLO icon

Summit Trail Advisors’s Xilio Therapeutics XLO Stock Holding History

Summit Trail Advisors’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,143
Closed -$17.3K – 677
2024
Q1 		$17.3K Buy
+1,143
New +$11K ﹤0.01% 609

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Summit Trail Advisors's XLO Position: Q2 2024 in Review

Summit Trail Advisors sold out of Xilio Therapeutics (XLO) in Q2 2024, closing a stake of 1,143 shares — an estimated $17.3K sold.

Summit Trail Advisors first reported a position in XLO in Q1 2024 and held it in 1 quarter. The position peaked at $17.3K in Q1 2024. 31 funds tracked by Wall St. Rank hold XLO as of Q2 2024.

  • Summit Trail Advisors reported no remaining Xilio Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Summit Trail Advisors sold 1,143 Xilio Therapeutics shares in Q2 2024, an estimated $17.3K.
  • Summit Trail Advisors first reported a position in Xilio Therapeutics in Q1 2024 and held it in 1 quarter.
  • Summit Trail Advisors's Xilio Therapeutics position peaked at $17.3K in Q1 2024.
  • 31 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2024.

Based on Summit Trail Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.